New stomach cancer treatment aims to shrink tumors before surgery
NCT ID NCT07408609
Summary
This study is testing if a combination of chemotherapy, low-dose radiation, and an immunotherapy drug (tislelizumab) given before and after surgery works better than chemotherapy alone for people with a certain type of advanced stomach cancer. The goal is to see if the new combination helps shrink or eliminate the tumor before surgery and lowers the chance of the cancer coming back. About 114 patients will be randomly assigned to receive either the new combination or standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.